ClinicalTrials.gg
WithdrawnNCT05344365Updated Mar 21, 2024

A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis

A Phase 2 interventional study of Iloperidone in Parkinson Disease Psychosis, sponsored by Vanda Pharmaceuticals. Withdrawn at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-03-21.

Sponsored by Vanda Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study was terminated for business reasons; not due to safety or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.

Enrollment
1,225th of 1,256
0 · median 36
Started
2022
with 104 others
Phase 2
234 of 1,649
25 open now
Registered
1,251st of 1,649
by date

Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 1,225th largest by enrollment of the 1,256 interventional ones that give a count, is one of 105 that started in 2022, is one of 234 in phase 2, and was the 1,251st registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

299 more — sign in →

All 304 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,649 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, sequential cohorts, flexible dose study to evaluate the tolerability, safety and pharmacokinetics of iloperidone in elderly patients with Parkinson's disease psychosis (PDP).

03

Conditions studied

  • Parkinson Disease Psychosis

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide consent and willing to complete all aspects of the study.
  • Male or female patients greater or equal to 65 years of age.
  • Clinical diagnosis of idiopathic Parkinson's disease with a minimum duration of 1 year
  • Psychotic symptoms for at least one month and actively experiencing psychotic symptoms each week during the month prior to screening

Exclusion criteria

Exclusion Criteria:

  • History of significant psychotic disorders prior to or concomitantly with the diagnosis of Parkinson's disease including, but not limited to, schizophrenia or bipolar disorder
  • Current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder, including cancer or , which would affect the patient's ability to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Iloperidone (Cohort 1)

    Drug: Iloperidone

  • Experimental
    Iloperidone (Cohort 2)

    Drug: Iloperidone

Interventions

  • oral tablet

    Also known as: VYV-683, FANAPT

06

What researchers measure

Primary outcomes

  1. Assessment of safety and tolerability of iloperidone in patients with Parkinson's disease psychosis.

    As measured by the incidence of adverse events and clinically significant changes in laboratory values, ECG parameters, and vital signs.

    Time frame: 8 days and 5 weeks

  2. Reduction in positive symptoms of Parkinson's disease psychosis.

    As measured by the Scale for the Assessment of Positive Symptoms for Parkinson's Disease Psychosis (SAPS-PD).

    Time frame: 8 days and 5 weeks

  3. Pharmacokinetics of iloperidone and its metabolites following oral treatment with iloperidone.

    As measured by plasma concentrations.

    Time frame: 8 days and 5 weeks

07

Study locations

1 site
  • Vanda Investigational Site
    Saint Petersburg, Florida 33713, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2022; primary completion for Nov 2023, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2022
First posted
Apr 25, 2022
StartEst.
Jun 2022
Primary completionEst.
Nov 2023
CompletionEst.
Nov 2023
Last update
Mar 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05344365
Responsible party
Sponsor
First posted
Apr 25, 2022
Start date
Jun 2022 (estimated)
Primary completion
Nov 2023 (estimated)
Completion
Nov 2023 (estimated)
Last update
Mar 21, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iloperidone

Start the discussion